PDXNet resources available for supplement application collaboration
NCI has issued a Program Announcement that will provide funding to enable non-PDXNet investigators to collaborate with PDXNet. The purpose of these awards, which would be awarded as supplements to existing qualifying NCI awards, is to make the resources of PDXNet available to the wider research community. The Program Announcement provides a more complete description of the program.
To help potential applicants identify opportunities for PDXNet collaboration, each of the PDX Development and Trial Centers (PDTCs) have provided a description of their PDTC's research goals as well as a description of their resources for the supplements. In addition, they have provided a list of models that will be made findable using PDXFinder (Table 1).
Scope of PDXNet supplement collaborations
The PDTC’s will receive limited supplemental funding to carry out their assigned collaborations with PDXNet supplement awardees. Listed below are examples of the scope and size of proposed projects that could be accomplished with the available funds. Proposed projects should not have a scope significantly larger than the examples below. However, these examples are not meant to be proscriptive; they are only provided to be illustrative of the feasible scope of proposed collaborations with PDXNet.
Drug testing in 5 PDX models with a single drug or in 2-3 PDX models with a drug combination. Since organoids are more efficient, drug testing in many organoids prior to or alongside PDX models could be performed in lieu of running one PDX model in vivo.
Drug testing can be performed in 4 phases. Phase 1 can be used to test the toxicity of 3 compounds (3 doses per compound) in 3 mice per group with 2 weeks observation time. Phase 2 can be used to test the efficacy of 3 compounds in 3 PDX models (4 groups of 10 mice each per PDX) with 8 weeks observation time. Phases 3 and 4 can each be used to test 2 compounds in 2 PDX models with 10 mice per group.
In vivo drug testing in 6-8 PDX models with 120 mice. Twenty to 25 of 120 NSG mice may be used for PDX passages, while the remaining NSG mice may be used for in vivo drug activity test, assuming 3 treatments/PDX model x 3 mice/treatment group.
Drug testing can be performed in 3 PDX models with a single drug in each PDX model or one drug in one PDX model with a humanized immune system. Testing a single drug in a PDX with a humanized immune system combination in a single PDX model would require 2 groups of10 mice each.